1. Home
  2. LEU vs ACAD Comparison

LEU vs ACAD Comparison

Compare LEU & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centrus Energy Corp.

LEU

Centrus Energy Corp.

HOLD

Current Price

$204.23

Market Cap

4.0B

Sector

Industrials

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.25

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEU
ACAD
Founded
1998
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.9B
IPO Year
1998
2000

Fundamental Metrics

Financial Performance
Metric
LEU
ACAD
Price
$204.23
$22.25
Analyst Decision
Buy
Buy
Analyst Count
12
22
Target Price
$248.82
$30.55
AVG Volume (30 Days)
707.1K
1.6M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
3.90
2.30
Revenue
$193,000,000.00
$726,437,000.00
Revenue This Year
$3.76
$18.80
Revenue Next Year
$6.04
$11.70
P/E Ratio
$51.94
$9.24
Revenue Growth
N/A
40.45
52 Week Low
$60.52
$14.08
52 Week High
$464.00
$28.35

Technical Indicators

Market Signals
Indicator
LEU
ACAD
Relative Strength Index (RSI) 55.05 51.74
Support Level $187.56 $20.22
Resistance Level $219.85 $23.06
Average True Range (ATR) 12.60 0.73
MACD 3.89 0.07
Stochastic Oscillator 86.38 69.59

Price Performance

Historical Comparison
LEU
ACAD

About LEU Centrus Energy Corp.

Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: